Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination product containing dexlansoprazole, lansoprazole, and amoxicillin, typically used for the eradication of *Helicobacter pylori* infection in patients with peptic ulcer disease. Dexlansoprazole and lansoprazole are proton pump inhibitors (PPIs) that reduce gastric acid production. Amoxicillin is a penicillin-class antibiotic.
## Primary Indications
* Eradication of *Helicobacter pylori* in patients with duodenal or gastric ulcers.
## Adult Dosing
The typical regimen for Sompraz HP is one capsule taken twice daily for 10 to 14 days. Each capsule contains dexlansoprazole 60 mg, lansoprazole 30 mg, and amoxicillin 500 mg.
## Pediatric Dosing
The use of Sompraz HP in pediatric patients has not been established. Dosing for *H. pylori* eradication in children depends on age, weight, and local resistance patterns and should be guided by specific pediatric guidelines.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment is recommended for dexlansoprazole or lansoprazole. However, amoxicillin is renally eliminated. In severe renal impairment (CrCl < 30 mL/min), the frequency of amoxicillin may need to be adjusted. Manufacturer information should be consulted for specific recommendations on amoxicillin dose adjustment in renal impairment.
* **Hepatic Impairment:** No specific dose adjustment is recommended for dexlansoprazole or lansoprazole in mild to moderate hepatic impairment. Caution and close monitoring are advised in severe hepatic impairment. Manufacturer information should be consulted.
## Contraindications
* Hypersensitivity to dexlansoprazole, lansoprazole, amoxicillin, other PPIs, or penicillins.
* History of severe hypersensitivity reaction to penicillin or other beta-lactam antibiotics.
* Use in patients with known penicillin allergy.
## Adverse Effects
Common adverse effects include diarrhea, nausea, abdominal pain, headache, and taste disturbances. More serious adverse effects can include severe allergic reactions, *Clostridioides difficile*-associated diarrhea, and potential for fractures with long-term PPI use.
## Key Drug Interactions
* **Clopidogrel:** PPIs may reduce the efficacy of clopidogrel. Consider alternative agents or concurrent use may be acceptable based on individual risk assessment.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **Ketoconazole, Itraconazole, Posaconazole:** PPIs can decrease absorption of these antifungals.
* **Certain HIV Protease Inhibitors:** PPIs may alter absorption of some protease inhibitors.
* **Mycophenolate Mofetil:** PPIs may decrease exposure to mycophenolate.
## Monitoring
* Monitor for signs and symptoms of *H. pylori* eradication (e.g., resolution of ulcer symptoms, urea breath test or stool antigen test at least 4 weeks after therapy completion).
* Monitor for adverse effects, particularly gastrointestinal upset and allergic reactions.
* Monitor renal function in patients with pre-existing renal impairment.
## Clinical Pearls
* Administer Sompraz HP as directed for the full duration of therapy to ensure *H. pylori* eradication.
* Patients should be advised to report any signs of severe diarrhea, rash, or other allergic reactions immediately.
* The combination of PPIs and amoxicillin is a standard regimen for *H. pylori* eradication, but resistance patterns can affect efficacy.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for complete details and to ensure patient safety.*
